Table 5 Comparison of responders versus non-responders with regard to cancer type, gender, prior treatment history, stage at diagnosis and baseline 25(OH)D levels (N = 799)
From: Impact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology
Characteristic | Responders (n = 441) | Non-responders (n = 358) | Chi-square p-value |
|---|---|---|---|
Cancer Site | Â | Â | Â |
   Breast | 103 (56.6) | 79 (43.4) |  |
   Lung | 83 (69.2) | 37 (30.8) |  |
   Pancreas | 28 (46.7) | 32 (53.3) | < 0.001 |
   Colorectal | 42 (46.7) | 48 (53.3) |  |
   Prostate | 42 (70) | 18 (30) |  |
   Others | 143 (49.8) | 144 (50.2) |  |
Gender | Â | Â | Â |
   Males | 153 (57.5) | 113 (42.5) | 0.35 |
   Females | 288 (54.0) | 245 (46.0) |  |
Treatment History | Â | Â | Â |
   Newly Diagnosed | 233 (56.8) | 177 (43.2) | 0.34 |
   Previously Treated | 208 (53.5) | 181 (46.5) |  |
Stage at Diagnosis | Â | Â | Â |
   Stage 0 | 3 (37.5) | 5 (62.5) |  |
   Stage 1 | 56 (52.8) | 50 (47.2) |  |
   Stage 2 | 91 (55.5) | 73 (44.5) | 0.82 |
   Stage 3 | 117 (56.3) | 91 (43.8) |  |
   Stage 4 | 139 (57) | 105 (43) |  |
   Indeterminate | 35 (55.2) | 34 (44.8) |  |
Baseline serum 25(OH)D | Â | Â | Â |
   < 12 ng/ml | 55 (35.3) | 101 (64.7) |  |
   12-20 ng/ml | 145 (55.1) | 118 (44.9) | < 0.001 |
   20-32 ng/ml | 241 (63.4) | 139 (36.6) |  |